• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

去乙酰头孢噻肟单独及与头孢噻肟联合应用的抗菌活性:协同作用证据

Antimicrobial activity of desacetylcefotaxime alone and in combination with cefotaxime: evidence of synergy.

作者信息

Jones R N, Barry A L, Thornsberry C

出版信息

Rev Infect Dis. 1982 Sep-Oct;4 Suppl:S366-73. doi: 10.1093/clinids/4.supplement_2.s366.

DOI:10.1093/clinids/4.supplement_2.s366
PMID:6294785
Abstract

The level of antimicrobial activity of 3-desacetylcefotaxime was found to be approximately eightfold lower than that of cefotaxime. Variation in the inhibitory effects of desacetylcefotaxime was species dependent. Desacetylcefotaxime was 1-2 log2 dilutions more active than cefotaxime against Pseudomonas acidovorans and Pseudomonas cepacia. Desacetylcefotaxime and cefotaxime were bactericidal, and their minimal inhibitory concentrations were influenced only slightly by increases in the inoculum concentration. Synergy (complete and partial) of 75.8% was noted with the combination. Only with strains of Morganella morganii was the combination antagonistic, but these results were not clinically significant; i.e., all strains remained susceptible to cefotaxime.

摘要

研究发现,3-去乙酰头孢噻肟的抗菌活性水平比头孢噻肟低约八倍。去乙酰头孢噻肟抑制作用的变化因菌种而异。去乙酰头孢噻肟对食酸假单胞菌和洋葱伯克霍尔德菌的活性比对头孢噻肟高1-2个对数2稀释度。去乙酰头孢噻肟和头孢噻肟具有杀菌作用,其最低抑菌浓度仅受接种物浓度增加的轻微影响。联合用药时观察到75.8%的协同作用(完全协同和部分协同)。仅摩根氏摩根菌菌株的联合用药具有拮抗作用,但这些结果在临床上并不显著;即所有菌株对头孢噻肟仍敏感。

相似文献

1
Antimicrobial activity of desacetylcefotaxime alone and in combination with cefotaxime: evidence of synergy.去乙酰头孢噻肟单独及与头孢噻肟联合应用的抗菌活性:协同作用证据
Rev Infect Dis. 1982 Sep-Oct;4 Suppl:S366-73. doi: 10.1093/clinids/4.supplement_2.s366.
2
Antibacterial activity of desacetylcefotaxime alone and in combination with cefotaxime.
Rev Infect Dis. 1982 Sep-Oct;4 Suppl:S374-8. doi: 10.1093/clinids/4.supplement_2.s374.
3
In vitro activity of desacetylcefotaxime and the interaction with its parent compound, cefotaxime.去乙酰头孢噻肟的体外活性及其与其母体化合物头孢噻肟的相互作用。
Drugs. 1988;35 Suppl 2:57-61. doi: 10.2165/00003495-198800352-00013.
4
Cefotaxime and desacetylcefotaxime: an example of advantageous antimicrobial metabolism.
Diagn Microbiol Infect Dis. 1984 Jun;2(3 Suppl):21S-31S.
5
Antimicrobial activity of ceftriaxone, cefotaxime, desacetylcefotaxime, and cefotaxime-desacetylcefotaxime in the presence of human serum.头孢曲松、头孢噻肟、去乙酰头孢噻肟及头孢噻肟-去乙酰头孢噻肟在人血清存在下的抗菌活性。
Antimicrob Agents Chemother. 1987 May;31(5):818-20. doi: 10.1128/AAC.31.5.818.
6
[In vitro synergy between cefotaxime and its main metabolite, desacetylcefotaxime].
Jpn J Antibiot. 1988 May;41(5):594-601.
7
The in vitro antimicrobial activity of desacetylcefotaxime compared to other related beta-lactams.去乙酰头孢噻肟与其他相关β-内酰胺类药物相比的体外抗菌活性。
Diagn Microbiol Infect Dis. 1984 Jun;2(3 Suppl):13S-20S.
8
In vitro synergy and potentiation between cefotaxime and desacetylcefotaxime against clinical isolates of Bacteroides.
Diagn Microbiol Infect Dis. 1984 Jun;2(3 Suppl):47S-53S.
9
Synergistic interaction between ofloxacin and cefotaxime against common clinical pathogens.
Infection. 1995 May-Jun;23(3):154-61. doi: 10.1007/BF01793856.
10
Cefotaxime and desacetylcefotaxime antimicrobial interactions. The clinical relevance of enhanced activity: a review.
Diagn Microbiol Infect Dis. 1995 May-Jun;22(1-2):19-33. doi: 10.1016/0732-8893(95)00043-a.

引用本文的文献

1
Physiologically Based Pharmacokinetic Model of Cefotaxime in Patients with Impaired Renal Function.肾功能受损患者头孢噻肟的生理药代动力学模型
Clin Pharmacokinet. 2025 Feb;64(2):257-273. doi: 10.1007/s40262-024-01469-x. Epub 2025 Jan 7.
2
Population Pharmacokinetics of Cefotaxime and Dosage Recommendations in Children with Sickle Cell Disease.头孢噻肟的群体药代动力学及镰状细胞病儿童的剂量推荐。
Antimicrob Agents Chemother. 2018 Mar 27;62(4). doi: 10.1128/AAC.00637-17. Print 2018 Apr.
3
Third generation cephalosporins in the parenteral to oral switch.
肠外给药转换为口服给药的第三代头孢菌素
Pharmacoeconomics. 1994;5(Suppl 2):27-33. doi: 10.2165/00019053-199400052-00006.
4
Criteria for testing the susceptibility of Streptococcus pneumoniae to cefotaxime and its desacetyl metabolite using 1 microgram or 30 micrograms cefotaxime disks.使用1微克或30微克头孢噻肟纸片检测肺炎链球菌对头孢噻肟及其去乙酰代谢物敏感性的标准。
Eur J Clin Microbiol Infect Dis. 1995 Aug;14(8):724-6. doi: 10.1007/BF01690885.
5
The antimicrobial activity of cefotaxime: comparative multinational hospital isolate surveys covering 15 years.头孢噻肟的抗菌活性:涵盖15年的多国医院分离株比较调查
Infection. 1994;22 Suppl 3:S152-60. doi: 10.1007/BF01782700.
6
Synergistic interaction between ofloxacin and cefotaxime against common clinical pathogens.
Infection. 1995 May-Jun;23(3):154-61. doi: 10.1007/BF01793856.
7
Antimicrobial activity of amikacin combinations against Enterobacteriaceae moderately susceptible to third-generation cephalosporins.阿米卡星联合用药对中度敏感于第三代头孢菌素的肠杆菌科细菌的抗菌活性。
Antimicrob Agents Chemother. 1982 Dec;22(6):985-9. doi: 10.1128/AAC.22.6.985.
8
Antimicrobial activity and other in vitro properties of cefoperazone A, the principal metabolite of cefoperazone sodium.头孢哌酮钠的主要代谢产物头孢哌酮A的抗菌活性及其他体外特性。
Antimicrob Agents Chemother. 1983 Aug;24(2):293-6. doi: 10.1128/AAC.24.2.293.
9
Influence of growth medium on the in vitro activities of second- and third-generation cephalosporins against Streptococcus faecalis.生长培养基对第二代和第三代头孢菌素体外抗粪肠球菌活性的影响。
J Clin Microbiol. 1984 Sep;20(3):561-7. doi: 10.1128/jcm.20.3.561-567.1984.
10
Cefotaxime. A review of its antibacterial activity, pharmacological properties and therapeutic use.头孢噻肟:抗菌活性、药理特性及治疗用途综述
Drugs. 1983 Mar;25(3):223-89. doi: 10.2165/00003495-198325030-00001.